Cost-effectiveness of implantable defibrillator as first-choice therapy versus electrophysiologically guided, tiered strategy in postinfarct sudden death survivors: A randomized study

Circulation

Volumn 93, Issue 3, 1996, Pages 489-496

  Wever, Eric F D ^a   Hauer, Richard N W ^a   Schrijvers, Guus ^a   Van Capelle, Frans J L ^b   Tijssen, Jan G P ^b   Crijns, Harry J G M ^c   Algra, Ale ^a   Ramanna, Hemanth ^a   Bakker, Patricia F A ^a   Robles De Medina, Etienne O ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

cost benefit analysis; death, sudden; defibrillation; electrophysiology; trials

Indexed keywords

ADULT; ARTICLE; CALCULATION; COST EFFECTIVENESS ANALYSIS; DEFIBRILLATOR; FOLLOW UP; HEALTH CARE COST; HEALTH CARE DELIVERY; HEART ELECTROPHYSIOLOGY; HEART GRAFT; HEART VENTRICLE ARRHYTHMIA; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; SUDDEN DEATH; SURVIVAL RATE;

EID: 0013480026     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.93.3.489     Document Type: Article

References (51)

1. Skale BT, Miles WM, Heger JJ, Zipes DP, Prystowsky EN. Survivors of cardiac arrest: prevention of recurrence by drug therapy as predicted by electrophysiologic testing or electrocardiographic monitoring. Am J Cardiol. 1986;57:113-119.
2. Waller TJ, Kay HR, Spielman SR, Kutalek SP, Greenspan AM, Horowitz LM. Reduction in sudden death and total mortality by antiarrhythmic therapy evaluated by electrophysiologic drug testing: criteria of efficacy in patients with sustained ventricular tachycardia. J Am Coll Cardiol. 1987;10:83-89.
3. Eldar M, Sauve MJ, Scheinman MM. Electrophysiologic testing and follow-up of patients with aborted sudden death. J Am Coll Cardiol. 1987;10:291-298.
4. Wilber DJ, Garan H, Finkelstein D, Kelly E, Newell J, McGovern B, Ruskin JN. Out-of-hospital cardiac arrest: use of electrophysiologic testing in the prediction of long-term outcome. N Engl J Med. 1988;318:19-24.
5. Knilans TK, Prystowsky EN. Antiarrhythmic drug therapy in the management of cardiac arrest survivors. Circulation. 1992;85(suppl I):I-118-I-124.
6. Mirowski M, Reid PR, Winkle RA, Mower MM, Watkins L Jr, Stinson EB, Griffith LSC, Kallman CH, Weisfeldt ML. Mortality in patients with implanted automatic defibrillators. Ann Intern Med. 1983;98:585-588.
7. Echt DS, Armstrong K, Schmidt P, Oyer PE, Stinson EB, Winkle RA. Clinical experience, complications, and survival in 70 patients with the automatic implantable cardioverter/defibrillator. Circulation. 1985;71: 289-296.
8. Fogoros N, Elson JJ, Bonnet CA, Fiedler SB, Burkholder JA. Efficacy of the automatic implantable cardioverter-defibrillator in prolonging survival in patients with severe underlying cardiac disease. J Am Coll Cardiol. 1990;16:381-386.
9. Akhtar M, Avitall B, Jazayeri M, Tchou P, Troup P, Sra J, Axtell K. Role of implantable cardioverter defibrillator therapy in the management of high-risk patients. Circulation. 1992;85(suppl I):I-131-I-139.
10. Kuppermann M, Luce BR, McGovern B, Podrid PJ, Bigger JT Jr, Ruskin JN. An analysis of the cost effectiveness of the implantable defibrillator. Circulation. 1990;81:91-100.
11. O'Donoghue S, Platia EV, Brooks-Robinson S, Mispireta L. Automatic implantable cardioverter-defibrillator: is early implantation cost-effective? J Am Coll Cardiol. 1990;16:1258-1263.
12. Saksena S, Camm AJ. Implantable defibrillators for prevention of sudden death: technology at a medical and economic crossroad. Circulation. 1992;85:2316-2321. Editorial.
13. Anderson MH, Camm AJ. Implications for present and future applications of the implantable cardioverter-defibrillator resulting from the use of a simple model of cost efficacy. Eur Heart J. 1993;69: 83-92.
14. Wever EFD, Hauer RNW, Crijns HJGM, Van Capelle FJL, Robles de Medina EO. Antiarrhythmic drugs as first option not warranted in survivors of cardiac arrest late after myocardial infarction. Circulation. 1993;88:I-118. Abstract.
15. Wever EFD, Hauer RNW, Crijns HJGM, Van Capelle FJL, Bakker PFA, Robles de Medina EO. Randomized study of conventional strategy versus implantable defibrillator as first-choice therapy in postinfarct sudden death survivors. Circulation. 1993;88(suppl I):I-156. Abstract.
16. Wever EFD, Hauer RNW, Van Capelle FL, Tijssen JGP, Crijns HJGM, Algra A, Wiesfeld ACP, Bakker PFA, Robles de Medina EO. Randomized study of implantable defibrillator as first-choice therapy versus conventional strategy in postinfarct sudden death survivors. Circulation. 1995;91:2195-2203.
17. O'Rourke RA. Current trends in clinical cardiology: a march of folly? Circulation. 1987;75:1097-1101. Editorial.
18. Sweeney MO, Ruskin JN. Mortality benefits and the implantable cardioverter-defibrillator. Circulation. 1994;89:1851-1858.
19. Wever EFD, Hauer RNW. Cost-effectiveness considerations: the Dutch prospective study of the automatic implantable cardioverter defibrillator as first-choice therapy. PACE Pacing Clin Electrophysiol. 1992;15:690-693.
20. Tchou PJ, Kadri N, Anderson J, Caceres JA, Jazayeri M, Akhtar M. Automatic implantable cardioverter defibrillators and survival of patients with left ventricular dysfunction and malignant ventricular arrhythmias. Ann Intern Med. 1988;109:529-534.
21. Hauser RG. The cost of tachyarrhythmia management. Arch Mal Coeur Vaiss. 1985;78:35-37.
22. Krucoff M, Chu F, McCallum D, Perry S. New medical technologies in a cost containment environment: implantable antitachyarrhythmia devices. PACE Pacing Clin Electrophysiol. 1987;10:2-20
23. Wever EFD, Hauer RNW, Oomen A, Peters RHJ, Bakker PFA, Robles de Medina EO. Unfavorable outcome in patients with primary electrical disease who survived an episode of ventricular fibrillation. Circulation. 1993;88:1021-1029.
24. Garan H, Nguyen K, McGovern B, Buckley M, Ruskin JN. Perioperative and long-term results after electrophysiologically directed ventricular surgery for recurrent ventricular tachycardia. J Am Coll Cardiol. 1986;8:201-209.
25. Van Hemel NM, Kingma JH, Defauw JAM, Vermeulen FE, Mast EG, Ernst JM, Ascoop CA. Left ventricular segmental wall motion score as a criterion for selecting patients for direct surgery in the treatment of postinfarction ventricular tachycardia. Eur Heart J. 1989;10:304-315.
26. Willems AR, Tijssen JGP, Van Capelle FJL, Kingma JH, Hauer RNW, Vermeulen FEE, Brugada P, Van Hoogcnhuyze DCA, Janse MJ. Determinants of prognosis in symptomatic ventricular tachycardia or ventricular fibrillation late after myocardial infarction. J Am Coll Cardiol. 1990;16:521-530.
27. Warner KF, Luce BR. Principles: the methodology of CBA-CEA. Cost-Benefit and Cost-Effectiveness Analysis in Health Care: Principles, Practice, and Potential. Ann Arbor, Mich: Health Administration Press; 1982:92.
28. Kupersmith J, Holmes-Rovner M, Hogan A, Rovner D, Gardiner J. Cost-effectiveness analysis in heart disease, part I: general principles. Prog Cardiovasc Dis. 1994;37:161-184.
29. Jung W, Manz M, Deister A, Lüderitz B. Quality of life in ICD recipients. Circulation. 1994;90(suppl I):I-499. Abstract.
30. Kim SG, Fisher JD, Furman S, Gross J, Zilo P, Roth JA, Ferrick KJ, Brodman R. Benefits of implantable defibrillators are overestimated by sudden death rates and better represented by the total arrhythmic death rate. J Am Coll Cardiol. 1991;17:1587-1592
31. Henthorn RW, Waller TJ, Hiratzka LF. Are the benefits of the automatic implantable cardioverter-defibrillator overestimated by sudden death rate? J Am Coll Cardiol. 1991;17:1593-1594. Editorial.
32. Ruskin JN, DiMarco JP, Garan H. Out-of-hospital cardiac arrest: electrophysiologic observations and selection of long-term antiarrhythmic therapy. N Engl J Med. 1980;303:607-613.
33. Denker S, Lehmann M, Mahmud R, Gilbert C, Akhtar M. Facilitation of ventricular tachycardia induction with abrupt changes in cycle length. Am J Cardiol. 1984;53:508-515.
34. Ruskin JN. Role of invasive electrophysiological testing in the evaluation and treatment of patients at high risk for sudden cardiac death. Circulation. 1992:85(suppl I):I-152-I-159.
35. Poole JE, Mathisen TL, Kudenchuk PJ, McAnulty JH, Swerdlow CD, Bardy GH, Greene HL. Long-term outcome in patients who survive out of hospital ventricular fibrillation and undergo electrophysiologic studies: evaluation by electrophysiologic subgroups. J Am Coll Cardiol. 1990;16:657-665.
36. Kim SG. Management of survivors of cardiac arrest: is electrophysiologic testing obsolete in the era of implantable defibrillators? J Am Coll Cardiol. 1990;16:756-762. Editorial.
37. Wasilewski SJ, Ferrick KJ, Borgen E, Roth JA, Kim SG, Fisher JD. The role of serial drug testing in patients with inducible polymorphic ventricular tachycardia. Pacing Clin Electrophysiol. 1994; 17:830. Abstract.
38. Mason JW, for the ESVEM Investigators. A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic drug efficacy for ventricular tachyarrhythmias. N Engl J Med. 1993;329:445-451.
39. DiMarco JP. Management of sudden cardiac death survivors: role of surgical and catheter ablation. Circulation. 1992;85(suppl I):I-125-I-130.
40. Epstein AE. AVID necessity. PACE Pacing Clin Electrophysiol. 1993;16:1773-1775.
41. Zipes DP Implantable cardioverter-defibrillator: lifesaver or a device looking for a disease? Circulation. 1994;89:2934-2936. Editorial.
42. Zipes DP. Are implantable cardioverter-defibrillators better than conventional antiarrhythmic drugs for survivors of cardiac arrest? Circulation. 1995;9:2115-2117. Editorial.
43. Conolly SJ, Jent M, Roberts RS, Dorian P, Green MS, Klein GJ, Mitchell LB, Sheldon RS, Roy D. Canadian Implantation Defibrillator Study (CIDS): study design and organization. Am J Cardiol. 1993;72:103F-108F.
44. Siebels J, Kuck KH. Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg). Am Heart J. 1994; 127:1139-1144.
45. Becker D, Block M, Isbruch F, Wietholt D, Hammel D, Borggrefe M, Breithardt G. Do patients with an implantable defibrillator live longer? J Am Coll Cardiol. 1993;21:1638-1644.
46. Block M, Hammel D, Borggrefe M, Isbruch F, Wietholt D, Hachenberg T, Scheld HH, Breithardt G. Transvenous-subcutaneous implantation of defibrillators as the approach of first choice. Circulation. 1991;84(suppl II):II-427. Abstract.
47. Guarnieri T, Cannom DS, Chapman PD, Chilson DA, Echt D S, Epstein AE, Furman S, Greer GS, Luceri RM, Maloney JD, Parsonnet V, Prystowsky EN, Ruskin JN, Veltri EP, Winkle RA. Multicenter experience: transvenous implantable cardioverter defibrillator lead system. Circulation. 1991;84(suppl II):II-428. Abstract.
48. Saksena S, for the PCD Investigator Group. Clinical outcome of patients with malignant ventricular tachyarrhythmias and a multi-programmable implantable cardioverter-defibrillator with or without thoracotomy: an international multicenter study. J Am Coll Cardiol. 1994;23:1521-1530.
49. Neuzner J, for the European Ventak P2 Investigator Group. Clinical experience with a new cardioverter defibrillator capable of biphasic waveform pulse and enhanced data storage: results of a prospective multicenter study. Pacing Clin Electrophysiol. 1994;17: 1243-1255.
50. Strickberger SA, Hummel JD, Daoud E, Niebauer M, Williamson BD, Man KC, Horwood L, Schmittou A, Kalbfleisch SJ, Langberg JJ, Morady F. Implantation by electrophysiologists of 100 consecutive cardioverter defibrillators with nonthoracotomy lead systems. Circulation. 1994;90:868-872.
51. Fitzpatrick AP, Lesh MD, Epstein LM, Lee RJ, Siu A, Merrick S, Griffin JC, Scheinman MM. Electrophysiological laboratory, electrophysiologist-implanted, nonthoracotomy-implantable cardioverter/defibrillators. Circulation. 1994;89:2503-2508.